What is Leap Therapeutics Inc Annual Net Profit?

Leap Therapeutics Inc Annual Net Profit rose 17.02% in the last year to $67.56 M. Its sector's average net profit growth for the last fiscal year was -32.62%.

What is Leap Therapeutics Inc Price to Earning Ratio?

Leap Therapeutics Inc Price to Earning Ratio is -0.16, which is negative.

What is Leap Therapeutics Inc Stock Price?

Leap Therapeutics Inc Stock Price fell 89.37% and underperformed its sector by 85.62% in the past year.

What is Leap Therapeutics Inc Quarterly Net profit?

Leap Therapeutics Inc Quarterly Net profit fell 23.79% YoY to $15.43 M. Its sector's average net profit growth YoY for the quarter was -47.55%.

What is Leap Therapeutics Inc Debt to Equity Ratio?

Leap Therapeutics Inc Debt to Equity Ratio of 0.01 is less than 1 and healthy. This implies that its assets are financed mainly through equity.

What is Leap Therapeutics Inc Return on Equity(ROE)?

Leap Therapeutics Inc Return on Equity(ROE) for the last financial year was -142.43%, less than 10%, indicating an inefficient use of shareholder's capital to generate profit.

What is Leap Therapeutics Inc Mutual Fund Holding?

Leap Therapeutics Inc Mutual Fund Holding decreased by 0.71% in the last quarter to 9.73.

What is Leap Therapeutics Inc Promoter Share Holding?

Leap Therapeutics Inc Promoter Share Holding increased by 0.58% in the most recent quarter to 0.97%.

What is Leap Therapeutics Inc Institutional Holding?

Leap Therapeutics Inc Institutional Holding remained the same in the last quarter at 32.7%.

How is the Leap Therapeutics Inc today?

The Leap Therapeutics Inc today is trading in the down by -6.90% at 0.27.

How has Leap Therapeutics Inc performed historically?

The Leap Therapeutics Inc is currently trading down -6.90% on an intraday basis in the past week the index fell -10.00%. The index has been down -92.24% in the past quarter and fell -89.37% in the past year. You can view this in the overview section.

Leap Therapeutics Inc XNAS: LPTX

Leap Therapeutics Inc Live Share Price Today, Share Analysis and Chart

Name: Leap Therapeutics Inc: Is Infosys Ltd. worth buying?
Item: Leap Therapeutics Inc
Rating: 0.78991675
Author: Trendlyne DVM scores

Download real time

0.27 -0.02 (-6.90%)

New 52W Low in past week

400.2K XNAS Volume

XNAS 08 Apr, 2025 5:30 PM (EDT)

Leap Therapeutics Inc Key Metrics

My Metrics

Default

Market Capitalization Low in industry Unavailable in chosen country	11.1
PE TTM Negative PE TTM Unavailable in chosen country	-0.2
Price to Book Below industry Median Unavailable in chosen country	0.3
Institutional holding current Qtr % Below industry Median Unavailable in chosen country	32.7
Net Profit Qtr Growth YoY % Negative Net Profit Qtr Growth YoY % Unavailable in chosen country	-23.8
Net Profit TTM Growth % Below industry Median Unavailable in chosen country	17
Piotroski Score Below industry Median Unavailable in chosen country	1
Rel Perf vs Sector quarter% Unavailable in chosen country	-85.4
ROE Annual % Negative ROE Annual % Unavailable in chosen country	-142.4
RoA Annual % Negative RoA Annual % Unavailable in chosen country	-111.2

All financials are in USD Million and price data in USD

Not Eligible

Expensive Valuation

14.7 / 100

Technically Bearish

16.9 / 100

No estimates available

Check Before You Buy

Check P/E Buy Sell Zone

This stock has negative PE

Leap Therapeutics Inc Stock Price Analysis

Day Price Range -6.9% 1 Day return Unavailable in chosen country	0.3 (LTP) 0.20.3 LowHigh
Week Price Range -10.0% 1 Week return Unavailable in chosen country	0.3 (LTP) 0.20.4 LowHigh
Month Price Range -38.6% 1 Month return Unavailable in chosen country	0.3 (LTP) 0.20.6 LowHigh
52 Week Price Range -89.4% 1 Year return Unavailable in chosen country	0.3 (LTP) 0.24.8 LowHigh

View full Share Price History

Leap Therapeutics Inc Live Price Chart

Switch to TradingView

Fetching data ...

Forecaster - Analyst Share Price Target and Estimates

Forecaster is a Premium Feature

You need to upgrade your subscription plan to access this feature

Upgrade Now

Leap Therapeutics Inc Stock Analysis

Leap Therapeutics Inc stock analysis with key metrics, changes, and trends.

Leap Therapeutics Inc Metric	VALUE	CHANGE %	TREND	ANALYSIS
Annual Net Profit	$67.56 M	17.02%	positive	Annual Net Profit rose 17.02% in the last year to $67.56 M. Its sector's average net profit growth for the last fiscal year was -32.62%.
Price to Earning Ratio	-0.16	-	negative	Price to Earning Ratio is -0.16, which is negative.
Stock Price	$0.27	-89.37%	negative	Stock Price fell 89.37% and underperformed its sector by 85.62% in the past year.
Quarterly Net profit	$15.43 M	23.79%	negative	Quarterly Net profit fell 23.79% YoY to $15.43 M. Its sector's average net profit growth YoY for the quarter was -47.55%.
Debt to Equity Ratio	0.01	-	positive	Debt to Equity Ratio of 0.01 is less than 1 and healthy. This implies that its assets are financed mainly through equity.
Return on Equity(ROE)	-142.43 %	-142.43%	negative	Return on Equity(ROE) for the last financial year was -142.43%, less than 10%, indicating an inefficient use of shareholder's capital to generate profit.
Mutual Fund Holding	9.73 %	-0.71%	negative	Mutual Fund Holding decreased by 0.71% in the last quarter to 9.73.
Promoter Share Holding	0.97 %	0.58%	positive	Promoter Share Holding increased by 0.58% in the most recent quarter to 0.97%.
Institutional Holding	32.70 %	0%	neutral	Institutional Holding remained the same in the last quarter at 32.7%.

VIEW LESS

Loading data..

Leap Therapeutics Inc - Company Profile

What does Leap Therapeutics Inc do?

Leap Therapeutics Inc is a biopharmaceutical company developing novel biomarker-targeted antibody therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways, targeting cancer-specific cell surface molecules, and harnessing the immune system to attack cancer cells. The company's key clinical-stage drug candidate is sirexatamab (DKN-01), which targets Dickkopf-related protein 1 (DKK1) and is being studied in a clinical trial in patients with colorectal cancer. In addition, it also has a preclinical program to develop a proprietary monoclonal antibody, called FL-501 which works by inhibiting the GDF-15 protein.

Leap Therapeutics Inc Management structure

All Gross Remunerations are in USD

Mr. Douglas E. Onsi

Director, Chief Executive Officer, Chief Financial Officer, President, Treasurer and Secretary

2024

Gross Remuneration

2024

Gross Remuneration

Year

Leap Therapeutics Inc Live Share Price Today, Share Analysis and Chart

New 52W Low in past week

Leap Therapeutics Inc Key Metrics

Market Capitalization

PE TTM

Price to Book

Institutional holding current Qtr %

Net Profit Qtr Growth YoY %

Net Profit TTM Growth %

Piotroski Score

Rel Perf vs Sector quarter%

ROE Annual %

RoA Annual %

Market Capitalization

PE TTM

Price to Book

Institutional holding current Qtr %

Net Profit Qtr Growth YoY %

Net Profit TTM Growth %

Piotroski Score

Rel Perf vs Sector quarter%

ROE Annual %

RoA Annual %

SWOT Analysis

Check Before You Buy

Check P/E Buy Sell Zone

Leap Therapeutics Inc Stock Price Analysis

Day Price Range

Week Price Range

Month Price Range

52 Week Price Range

Leap Therapeutics Inc Live Price Chart

Forecaster - Analyst Share Price Target and Estimates

Revenue forecast

Leap Therapeutics Inc Stock Analysis

Leap Therapeutics Inc stock analysis with key metrics, changes, and trends.

Annual Net Profit rose 17.02% in the last year to $67.56 M. Its sector's average net profit growth for the last fiscal year was -32.62%.

Price to Earning Ratio is -0.16, which is negative.

Stock Price fell 89.37% and underperformed its sector by 85.62% in the past year.

Quarterly Net profit fell 23.79% YoY to $15.43 M. Its sector's average net profit growth YoY for the quarter was -47.55%.

Debt to Equity Ratio of 0.01 is less than 1 and healthy. This implies that its assets are financed mainly through equity.

Return on Equity(ROE) for the last financial year was -142.43%, less than 10%, indicating an inefficient use of shareholder's capital to generate profit.

Mutual Fund Holding decreased by 0.71% in the last quarter to 9.73.

Promoter Share Holding increased by 0.58% in the most recent quarter to 0.97%.

Institutional Holding remained the same in the last quarter at 32.7%.

Leap Therapeutics Inc - Company Profile

What does Leap Therapeutics Inc do?

Leap Therapeutics Inc Management structure

Mr. Douglas E. Onsi

Director, Chief Executive Officer, Chief Financial Officer, President, Treasurer and Secretary

Leap Therapeutics Inc Board of directors

Dr. Joseph Loscalzo, M.D.,PhD

Independent Director

Mr. Nissim Mashiach

Independent Director

Dr. James H. Cavanaugh,PhD

Independent Director

Dr. Christopher K. Mirabelli, PhD

Chairman of the Board

Dr. Thomas J. Dietz, PhD

Lead Independent Director

Mr. Douglas E. Onsi

Director, Chief Executive Officer, Chief Financial

Leap Therapeutics Inc FAQ

How is Leap Therapeutics Inc today?

Leap Therapeutics Inc today is trading in the red, and is down by -6.90% at 0.27.

How has Leap Therapeutics Inc performed historically?

Leap Therapeutics Inc is currently trading down -6.90% on an intraday basis. In the past week the stock fell -10.00%. stock has been down -92.24% in the past quarter and fell -89.37% in the past year. You can view this in the overview section.